Moreover, a cross-sectional study including 101 patients with T1DM and 96 with T2DM (patients in both case and control groups had diabetes, and they were grouped according to whether they had a vertebral fracture or incident fracture) demonstrated that sclerostin had different effects on the bone turnover of patients with T1DM and T2DM, which negatively correlated with the fracture occurrence in patients with T1DM, but positively correlated with the fracture occurrence in patients with T2DM (82). This evidence concerns the gene SOST and type 1 diabetes mellitus.